Sponsor:
Vanderbilt-Ingram Cancer Center
Code:
NCT07673367
Conditions
Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Nemtabrutinib
Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus)
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-11. This information was provided to ClinicalTrials.gov by Vanderbilt-Ingram Cancer Center on 2026-08-05.